Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST-1898 tablets plus everolimus or belzutifan in advanced renal cell carcinoma after failure of first-line standard therapy
CTR20263148Phase 2Active
- Sponsor
- Beijing Scitech-MQ Pharmaceuticals Limited
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ACC-1898 in renal cell carcinoma (RCC), sponsored by Beijing Scitech-MQ Pharmaceuticals Limited. Started Aug 2026; status: active.
02
Drugs
ACC-1898
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on CTR20263148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263148.